Electromedical and Electrotherapeutic Apparatus Manufacturing (NAICS 334510)

A Histometrics industry primer for public-market and private investors.

1. Overview

This is the part of the U.S. medical-device industry that makes machines and implants that diagnose or treat the body with electricity, magnetism, sound, or light — pacemakers and defibrillators, MRI (magnetic resonance imaging) and ultrasound scanners, patient monitors, electrocardiographs (ECG/EKG machines that record the heart's electrical activity), hearing aids and cochlear implants, deep-brain and spinal-cord stimulators, and continuous glucose monitors (CGMs, wearable sensors that track blood sugar).[1] If a device has electronics inside and touches a patient's diagnosis or therapy, it usually lands here.

Why an investor cares: it is a large, durable, high-margin, innovation-driven slice of health care. Demand rises with an aging population and chronic disease, revenue is protected by patents and hard-won regulatory approvals, and much of the money is recurring — disposables, implant replacements, service contracts, and software subscriptions on an installed base of equipment. It is also cyclical at the margins (hospital capital budgets) and heavily shaped by government reimbursement.

Public vs. private ways in. The public route is unusually deep: several of the world's largest device makers are U.S.-listed (Medtronic, Abbott, GE HealthCare, Boston Scientific), alongside focused pure-plays (Dexcom, Masimo, iRhythm) and foreign-listed giants (Siemens Healthineers, Philips, Sonova, Cochlear) that manufacture and sell heavily in the U.S. The private route is dominated by venture-backed device startups — most of which exist to be acquired by the majors — plus contract manufacturers and private specialists such as pacemaker maker BIOTRONIK. Details are in sections 4 and 10.

2. What it is and how it's structured

In scope (NAICS 334510): establishments whose primary product is electromedical or electrotherapeutic apparatus — diagnostic imaging (MRI, ultrasound, and the electronics of X-ray/CT systems), cardiac rhythm devices (pacemakers, implantable defibrillators), patient monitoring, electrosurgical and electrotherapy units (including TENS — transcutaneous electrical nerve stimulation), neuromodulation implants, hearing aids and hearing implants, endoscopic electronics, and ECG/EEG (electroencephalograph, which records brain activity) equipment.[1]

What it excludes — this matters for sizing the industry and picking comparables:

• Irradiation apparatus (X-ray tubes, CT gantries as radiation emitters, radiation-therapy machines) is NAICS 334517, a separate code.[1]
• Non-electronic medical and surgical instruments and supplies — catheters, stents, syringes, orthopedic implants, hospital furniture, disposables — sit in NAICS 339112–339113 (Medical Equipment and Supplies Manufacturing).[1] This is a critical exclusion: a company like Boston Scientific or Abbott books revenue across both 334510-type electronic devices and 339112-type mechanical devices, so no single NAICS code captures a diversified device maker.
• In-vitro diagnostics / lab analyzers, dental equipment, and eyewear are elsewhere again.

Operating models within the code. The products fall into four broad categories with distinct economics. Large capital systems (MRI, cart-based ultrasound, patient-monitoring networks) are sold to hospitals and imaging centers through lengthy procurement, bundling installation, training, IT integration, warranties, and multiyear service. Implantable products (pacemakers, neurostimulators) depend on clinical evidence, regulatory approval, physician training, and procedure volumes. Wearable or patient-operated products (hearing aids, CGMs) combine electronics with recurring replacement components, software, and distribution through clinicians, pharmacies, durable-medical-equipment channels, or direct-to-consumer. Electromedical endoscopy and monitoring equipment mixes durable hardware, accessories, and service.[2]

A representative manufacturer therefore does considerably more than fabricate electronics: it develops hardware and embedded software, sponsors clinical work, validates suppliers and production processes, obtains regulatory authorization, trains clinicians, maintains field-service capacity, and conducts post-market surveillance. GE HealthCare illustrates the hardware-plus-lifecycle model: it recorded $13.7 billion of product sales and $7.0 billion of service sales in 2025, ending the year with $5.0 billion of product-related remaining performance obligations and $10.7 billion of service-related obligations.[2]

Ownership mix. The federal data count 822 firms operating 892 establishments,[3][4] which looks like a fragmented, mostly single-site industry — and at the bottom it is (many small specialist and contract shops). But revenue and profit are concentrated in a handful of multinationals whose electromedical output is only part of a much larger, multi-code medical-technology business. Most are C-corporations; the largest are publicly traded, with private and foreign-owned players filling specific niches (cardiac rhythm, hearing, imaging components).

3. How big it is

U.S. federal statistics for NAICS 334510:

That works out to roughly $119,000 in average annual pay and well over $480,000 of receipts per worker — the signature of a capital- and intellectual-property-intensive industry where value comes from engineering and regulatory approval, not headcount.[5] The U.S. Small Business Administration's size standard for this industry is 1,250 employees, unusually high, reflecting how capital-heavy even a "small" device maker is.[7] BLS's separate establishment survey shows 72,800 employees in June 2025 and 75,000 in May 2026; the difference from AIES reflects different programs, reference periods, and reporting units.[8]

Undercount and scope caveats — read these before comparing figures.

• The $45.5 billion is U.S. employer-firm output (what U.S. establishments ship). It is not the same as U.S. demand: private analysts put the U.S. electro-medical and electrotherapeutic apparatus market (domestic consumption) at about $26.3 billion in 2024.[9] Receipts exceed domestic consumption because the U.S. is a major exporter of high-end devices (pacemakers, implants, imaging), even as it imports many finished imaging systems — the country runs a rough trade balance in medical instruments overall, exporting about $35.8 billion and importing about $41.3 billion in 2024.[10]
• The federal code understates the household-name device giants. A company is classified by its primary product, so Medtronic, Abbott, Boston Scientific, and Johnson & Johnson report the bulk of their revenue under other codes even though they are the dominant electromedical manufacturers. The industry's true economic weight is far larger than the 334510 line alone suggests.
• Globally, the electro-medical and electrotherapeutic apparatus market is estimated at roughly $66–71 billion in 2024–2025, growing about 6–7% a year, with North America the largest region (~41%).[11]

4. The investable universe

This is a rich public universe. The table below lists the most relevant U.S.-listed names; foreign majors and private players follow. Revenue figures are total company or the relevant device segment as noted — most of these firms span 334510 electromedical products and other device codes, so treat the numbers as scale indicators, not pure 334510 sales.

Foreign-listed majors that build and sell heavily in the U.S. (available to U.S. investors via home-market shares or ADRs — American Depositary Receipts, foreign shares traded on U.S. exchanges): Siemens Healthineers (Germany) and Philips (Netherlands) in imaging and monitoring; Sonova and Demant in hearing aids; Cochlear (Australia) in hearing implants; Nihon Kohden (Japan) in monitoring.[2][19]

Major private and other owners: BIOTRONIK (private, Germany) in pacemakers and defibrillators; WS Audiology and Starkey in hearing aids; Natus Medical (taken private) in neurodiagnostics; plus a long tail of venture-backed startups and contract manufacturers. Because the majors grow largely by buying these private innovators, the private universe is best understood as the industry's R&D pipeline and M&A supply.

ETFs for one-click diversification include the iShares U.S. Medical Devices ETF (IHI) and the SPDR S&P Health Care Equipment ETF (XHE); their mandates extend beyond 334510 into surgical instruments, orthopedics, and supplies, so neither should be treated as a pure tracker for the NAICS industry.[20][21]

5. How the money works

Owners in this industry make money on a few distinct economic engines:

• Razor-and-blade recurring revenue. The most attractive model. Sell (or place) a durable product, then earn a steady annuity on disposables and services: implanted pacemakers and defibrillators get replaced every ~5–12 years; CGM sensors are consumed every 10–15 days; imaging systems carry multi-year service contracts; digital-health devices add software subscriptions. This recurring layer smooths revenue and lifts margins.
• High gross margins, heavy reinvestment. Gross margins run from roughly 40% for capital imaging (GE HealthCare) to 60–70% for implantables and monitoring (Boston Scientific ~69%, Dexcom ~60%).[2][15][16] Companies plow 6–10% of revenue back into R&D — GE HealthCare ~6%, Medtronic ~8.5%, Boston Scientific ~10% — because a fresh clearance or approval is the moat.[2][22] Operating margins vary widely by product mix: GE HealthCare's segment EBIT margins in 2025 ranged from 9–10% for Imaging and Patient Care Solutions to ~25% for Advanced Visualization Solutions; Abbott's Medical Devices segment achieved 33.7% operating margin in 2025.[2][14]
• Installed base and switching costs. Once a hospital standardizes on an imaging vendor or an electrophysiology mapping system, retraining and integration costs lock it in. Placing the base cheaply to win the annuity is a common play.
• Reimbursement is the real customer. Volumes ultimately depend on whether CMS (the Centers for Medicare & Medicaid Services, the federal health-insurance agency) and private payers cover the procedure and pay enough. A new device with a clearance but no reimbursement code sells poorly; a favorable payment pathway can unlock a market overnight (see Regulation).

Key cost drivers include precision electronic components, sensors, batteries, magnets, printed circuit assemblies, specialty metals, software development, clinical studies, regulatory and quality functions, warranty expense, field service, and technically skilled labor. Imaging companies also face exposure to helium and rare-earth minerals; GE HealthCare reports sole- and single-source dependencies and specifically identifies helium, iodine, and rare-earth minerals as volatile inputs.[2]

Key metrics investors track: procedure volumes and installed-base growth; new-product cadence (clearances/approvals per year); recurring-revenue mix; gross and operating margin; R&D intensity; and, for pipeline names, clinical-trial readouts and time-to-reimbursement.

6. What drives demand

• Demographics and chronic disease. An aging population and rising rates of cardiovascular disease, diabetes, cancer, and neurological conditions are the structural tailwind — cardiology alone is the single largest application segment (~27% of the market).[11] The U.S. population aged 65 and older reached 61.2 million in 2024, up 3.1% in one year, and represented 18.0% of the population versus 12.4% in 2004.[23] NIDCD reports disabling hearing loss among 22% of people aged 65–74 and 55% of those aged 75 and older.[24] During August 2021–August 2023, total diabetes prevalence was 15.8% among U.S. adults, including diagnosed prevalence of 11.3% and undiagnosed prevalence of 4.5%.[25]
• Procedure volumes. Most revenue is tied to a clinical procedure (an ablation, an implant, a scan), so anything that raises or lowers procedure counts — clinical capacity, staffing, patient backlogs — moves the industry.
• Reimbursement and coverage. Coverage decisions and payment rates from CMS and insurers set the addressable market for each device (section 7).
• Hospital and clinic capital cycles. Big-ticket imaging is bought out of capital budgets, which flex with hospital finances and interest rates — the cyclical part of an otherwise defensive industry.
• Technology shifts. Minimally invasive and implantable therapies, remote/wearable monitoring, and AI (artificial intelligence) embedded in diagnostics and decision support are expanding both what devices can do and what payers will pay for.[11] Leadless cardiac implants, pulsed-field ablation, handheld ultrasound, and continuous sensing are durable trends.
• Replacement cycles. Implant battery life and equipment obsolescence create predictable repurchase demand independent of new-patient growth.
• Healthcare spending trajectory. CMS projects national health expenditures to grow 5.4% annually over 2025–2034 (versus 4.1% GDP growth), taking health spending from 18.0% of GDP in 2024 to 20.6% in 2034; Medicare is projected to be the fastest-growing major funding source at 7.7% annually.[26]

7. Regulation

The industry is gated by the FDA (Food and Drug Administration), specifically its CDRH (Center for Devices and Radiological Health). Devices are sorted into three risk classes, and the market-entry pathway follows the class:[27]

• Class I (low risk): mostly exempt from premarket review.
• Class II (moderate risk — most monitors, imaging, many therapeutic devices): cleared via a 510(k), a premarket notification showing the device is "substantially equivalent" to a legally marketed predicate device. Faster and cheaper; usually no new human trial.[27]
• Class III (highest risk — pacemakers, defibrillators, many implants): require PMA (premarket approval), the most rigorous pathway, backed by clinical trial evidence of safety and effectiveness.[27] Newer routes include De Novo (for novel low/moderate-risk devices with no predicate) and the Breakthrough Devices program for expedited review.

Four regulatory frontiers matter now:

• Cybersecurity. Since March 29, 2023, under section 524B of federal law, any "cyber device" (software-containing, internet-connectable) must include a vulnerability-management plan, processes for updates and patches, and a software bill of materials in its premarket submission; the FDA can refuse to accept submissions that don't comply.[28] This raises the bar for the industry's fast-growing connected and AI-enabled products.
• Quality Management System Regulation (QMSR). FDA's QMSR became effective on February 2, 2026 and incorporates ISO 13485:2016. FDA can now inspect management-review, quality-audit, and supplier-audit records that previously received different treatment under the old regulation.[29]
• Reimbursement pathways. Getting paid is a second gauntlet run mostly through CMS. Mechanisms include NTAP (New Technology Add-on Payment, extra hospital payment for qualifying new tech), the TCET pathway (Transitional Coverage for Emerging Technologies, to speed Medicare coverage of Breakthrough Devices), and the newer RAPID program aiming to align FDA authorization and Medicare coverage decisions within months rather than years.[30] These pathways are a genuine forward catalyst if they shorten the gap between approval and revenue.
• OTC hearing aids. FDA's over-the-counter hearing-aid framework, effective October 17, 2022, enables new retail channels and lower-cost competition against the traditional audiology model — a concrete example of regulation reshaping competitive dynamics.[31]

Note on taxes: the 2.3% medical-device excise tax created under the Affordable Care Act was suspended for years and then permanently repealed in December 2019, removing a direct drag on device-maker margins.[32]

8. Competitive dynamics and consolidation

The federal concentration statistics look benign: the top 4 firms hold 28.6% of receipts, the top 8 hold 40%, the top 20 hold 57.8%, and the industry's HHI is just 297.6 (the Herfindahl-Hirschman Index, a 0–10,000 concentration score; anything under 1,500 is "unconcentrated" by U.S. antitrust standards).[4]

That top-line number is misleading about real competition. Because the code lumps together dozens of unrelated product niches, no single firm looks dominant across the whole code — yet each individual product market is a tight oligopoly. Pacemakers and defibrillators are effectively a handful of firms (Medtronic, Abbott, Boston Scientific, BIOTRONIK); hearing devices are led by Sonova, Demant, WS Audiology, GN, Starkey, and Cochlear (roughly 80% of that market between them);[19] high-end imaging is GE HealthCare, Siemens Healthineers, Philips, United Imaging, Mindray, and Canon — GE HealthCare names those companies as principal competitors.[2] Within its niche, each leader enjoys pricing power, scale in R&D, and entrenched installed bases.

Consolidation runs on a "buy the innovation" model. The majors generate a large share of growth by acquiring venture-backed startups that have de-risked a novel technology. Recent examples: Johnson & Johnson's ~$13.1 billion purchase of Shockwave Medical (intravascular lithotripsy, which uses sound-pressure waves to break arterial calcium), and Boston Scientific's string of deals (Axonics in urinary/bowel neuromodulation, Silk Road Medical in stroke prevention, Bolt Medical in lithotripsy).[33] Medtech dealmaking rebounded sharply in 2024–2025 after a post-pandemic lull.[33] For investors, this creates two distinct plays: own the acquirers for compounding scale, or own (or back) the innovators as acquisition targets.

9. Risks

• Regulatory and recall risk. A delayed approval, a Class I recall, or a clinical-trial miss can erase a product line's value; cybersecurity and quality-system requirements keep rising.[27][28][29]
• Reimbursement risk. Coverage denials or payment cuts by CMS and private payers can strand an approved device with no viable market — reimbursement, not clearance, is often the true gate. Dexcom disclosed that a 2025 CMS proposal could subject continuous glucose monitors to competitive bidding and produce price reductions.[16][30]
• Product-liability and litigation. Implanted and life-sustaining devices carry large tort and warning-letter exposure.
• Tariffs and supply chain. Imaging systems and components are built across Mexico, the EU, and China. GE HealthCare estimated that tariffs reduced its 2025 operating income by approximately $245 million and cash flow by approximately $285 million;[2] Siemens Healthineers and Philips projected impacts of hundreds of millions of euros each.[34] Qualified components cannot always be replaced quickly: changing a supplier or component may require redesign, validation, and a new regulatory submission. FDA identifies manufacturing and quality problems, geopolitical events, natural disasters, delivery delays, and product discontinuations as causes of device shortages.[35]
• Hospital capital sensitivity. Big-ticket equipment demand softens when hospital budgets and credit tighten — the cyclical soft spot.
• Competition and pricing pressure. Niche oligopolies still face price erosion as products commoditize and payers push value-based purchasing.
• Technology disruption. Software, AI, and at-home/wearable formats can obsolete installed hardware — a threat to incumbents and an opening for entrants.
• FX and concentration. Global sales expose earnings to currency swings, and dependence on a few blockbuster franchises magnifies single-product setbacks.

10. How to invest and the outlook

Public-market routes.

• Diversified large caps for broad, defensive exposure: Medtronic (MDT), Abbott (ABT), GE HealthCare (GEHC), Boston Scientific (BSX), Johnson & Johnson (JNJ).[2][12][14][15] Several — notably Abbott and Medtronic — are long-standing dividend payers, appealing to income investors.
• Focused pure-plays for higher growth and higher volatility: Dexcom (DXCM) in glucose monitoring, Masimo (MASI) in patient monitoring, iRhythm (IRTC) in cardiac monitoring.[16][17][18]
• Foreign majors via home listings or ADRs: Siemens Healthineers, Philips, Sonova, Demant, Cochlear, Nihon Kohden.[2][19]
• ETFs for one-click diversification: iShares U.S. Medical Devices ETF (IHI) and SPDR S&P Health Care Equipment ETF (XHE), which hold most of the names above but extend beyond 334510.[20][21]

Private-market routes.

• Venture capital into device startups is the classic private play — returns come mostly from acquisition by a strategic rather than IPO, so exit timing tracks the majors' M&A appetite.[33]
• Private equity roll-ups of contract manufacturers / CDMOs (contract development and manufacturing organizations that build devices for others) and specialty distributors.
• Direct/private ownership of niche specialists (e.g., BIOTRONIK-style cardiac firms, hearing-aid makers) where scale and regulatory know-how are the moat. Critical diligence items include regulatory status, reimbursement, clinical evidence, installed-base retention, consumable attachment, customer concentration, supplier qualification, inspection history, complaint and recall trends, cybersecurity obligations, and whether approvals can be maintained after a manufacturing-site or ownership change.

Near-term drivers (forward-looking). The structural growth case — aging demographics, chronic disease, recurring-revenue models — remains intact, and mid-single-digit annual market growth is the consensus expectation.[9][11] Watch three swing factors: (1) reimbursement modernization (TCET/RAPID) potentially shortening approval-to-payment lag and pulling forward revenue;[30] (2) tariffs and supply-chain reshoring, a genuine 2025–2026 margin headwind for import-heavy imaging hardware;[2][34] and (3) the pace of AI integration and connected/wearable devices, which is simultaneously the biggest growth vector and the source of new cybersecurity and competitive risk.[11][28] Continued M&A by cash-rich majors buying private innovators is the most reliable base-case expectation. Net: a defensive, compounding industry with real cyclical and policy sensitivities — attractive for patient capital on both the public and private sides, provided the reimbursement and regulatory gates are respected.

---

Sources

1. U.S. Census Bureau, "NAICS Code 334510 — Electromedical and Electrotherapeutic Apparatus Manufacturing (definition, scope, exclusions)," 2022. https://www.census.gov/naics/?details=334510&input=334510&year=2022
2. GE HealthCare Technologies, Form 10-K for fiscal year ended December 31, 2025. https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm
3. U.S. Census Bureau, County Business Patterns, NAICS 334510 (establishments), 2023. https://www.census.gov/programs-surveys/cbp.html
4. U.S. Census Bureau, 2022 Economic Census — Concentration statistics, NAICS 334510 (receipts, firm count, CR4/CR8/CR20/CR50, HHI), 2022. https://www.census.gov/programs-surveys/economic-census.html
5. U.S. Census Bureau, Annual Integrated Economic Survey, NAICS 334510 (sales, employment, payroll), 2023. https://data.census.gov/table/AIESBASICTIMESERIES.AIES00BASIC?codeset=naics~334510&g=010XX00US
6. U.S. Census Bureau, Annual Integrated Economic Survey — Inventory data, NAICS 334510, 2023. https://data.census.gov/table/AIESMISCSECTORTIMESERIES.AIES31INV?codeset=naics~334510&g=010XX00US
7. U.S. Small Business Administration, "Table of Size Standards," NAICS 334510 (1,250 employees), 2023. https://www.sba.gov/document/support-table-size-standards
8. U.S. Bureau of Labor Statistics, Table B-1b, Employees on nonfarm payrolls by detailed industry, 2025–2026. https://www.bls.gov/web/empsit/ceseeb1b.htm
9. Grand View Research, "U.S. Electro-medical And Electrotherapeutic Apparatus Market ($26.25B in 2024, to $37.91B by 2030)," 2024. https://www.grandviewresearch.com/industry-analysis/us-electro-medical-electrotherapeutic-apparatus-market-report
10. Observatory of Economic Complexity, "Medical Instruments (HS 9018) — U.S. exports $35.8B / imports $41.3B," 2024. https://oec.world/en/profile/hs/medical-instruments
11. Grand View Research, "Electro-medical And Electrotherapeutic Apparatus Market (global ~$66B 2024, ~6.4% CAGR; cardiology & North America shares)," 2024. https://www.grandviewresearch.com/industry-analysis/electro-medical-electrotherapeutic-apparatus-market-report
12. Medtronic plc, "Medtronic reports fiscal 2025 financial results," 2025. https://news.medtronic.com/2025-02-18-Medtronic-reports-third-quarter-fiscal-2025-financial-results
13. MassDevice, "The 10 largest medical device companies" (J&J MedTech ~$33.8B; industry ranking), 2025. https://www.massdevice.com/largest-medical-device-companies-2025/
14. Abbott Laboratories, Form 10-K for fiscal year ended December 31, 2025 (Medical Devices segment $21.387B, 33.7% operating margin). https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm
15. Boston Scientific Corporation, Form 10-K for fiscal year ended December 31, 2025 ($20.074B sales, $13.854B gross profit). https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm
16. Dexcom, Inc., Form 10-K for fiscal year ended December 31, 2025 ($4.662B revenue); 2025 Form 10-K noting CMS competitive bidding proposal. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm
17. Masimo Corporation, "Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results" ($2.094B), 2025. https://investor.masimo.com/news/news-details/2025/Masimo-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Updated-Full-Year-2025-Guidance/default.aspx
18. iRhythm Technologies, "iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results" ($591.8M, +20.1%), 2025. https://www.globenewswire.com/news-release/2025/02/20/3030075/0/en/iRhythm-Technologies-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
19. MarketsandMarkets, "Hearing Aids Market — top players (Sonova, Demant, Cochlear, GN, Starkey, WS Audiology; ~80% share)," 2025. https://www.marketsandmarkets.com/Market-Reports/hearing-aids-market-198630754.html
20. iShares, "iShares U.S. Medical Devices ETF (IHI)." https://www.ishares.com/us/products/239516/ishares-us-medical-devices-etf
21. State Street Global Advisors, "SPDR S&P Health Care Equipment ETF (XHE)." https://www.ssga.com/us/en/individual/etfs/funds/spdr-sp-health-care-equipment-etf-xhe
22. R&D World / Medical Design & Outsourcing, "Medtech R&D intensity (~8–10% of sales) and gross margins," 2024. https://www.rdworldonline.com/how-medtech-often-gets-more-innovation-bang-for-its-rd-buck/
23. U.S. Census Bureau, "2024 Population Estimates — Older adults outnumber children" (61.2M aged 65+, 18.0% of population), 2025. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html
24. National Institute on Deafness and Other Communication Disorders, "Quick Statistics About Hearing" (hearing loss prevalence by age), 2024. https://www.nidcd.nih.gov/health/statistics/quick-statistics-hearing
25. CDC/NCHS, "Diabetes Prevalence Among U.S. Adults" (15.8% total prevalence, Aug 2021–Aug 2023), 2024. https://www.cdc.gov/nchs/products/databriefs/db516.htm
26. Centers for Medicare & Medicaid Services, "National Health Expenditure Fact Sheet" (5.4% annual growth 2025–2034, 20.6% of GDP by 2034), 2025. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
27. U.S. Food and Drug Administration, "Classify Your Medical Device" (device classes and pathways), 2025. https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
28. U.S. Food and Drug Administration, "Cybersecurity in Medical Devices: Frequently Asked Questions" (section 524B, effective March 29, 2023), 2025. https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs
29. U.S. Food and Drug Administration, "Quality Management System Regulation (QMSR)" (effective February 2, 2026, incorporating ISO 13485:2016), 2026. https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
30. Centers for Medicare & Medicaid Services, "New Medical Services and New Technologies (NTAP); Transitional Coverage for Emerging Technologies (TCET); RAPID program," 2025. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/new-medical-services-and-new-technologies
31. U.S. Food and Drug Administration, "Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products" (OTC hearing aid rule, effective October 17, 2022), 2022. https://www.fda.gov/media/163084/download
32. Fierce Biotech, "It's done: U.S. repeals the medical device excise tax" (2.3% tax permanently repealed Dec. 2019), 2019. https://www.fiercebiotech.com/medtech/it-s-done-u-s-repeals-medical-device-excise-tax
33. MedTech Dive, "J&J to acquire Shockwave Medical for $13.1B" and 2024–2025 medtech M&A activity, 2024–2025. https://www.medtechdive.com/news/jnj-shockwave-medical-acquisition/712374/
34. Fierce Biotech, "Siemens Healthineers, Philips project tariff hit" (hundreds of millions of euros, 2025–2026), 2025. https://www.fiercebiotech.com/medtech/siemens-healthineers-philips-project-softer-tariff-hit-following-us-eu-deal
35. U.S. Food and Drug Administration, "Medical Device Supply Chain and Shortages," 2025. https://www.fda.gov/medical-devices/medical-device-safety/medical-device-supply-chain-and-shortages